<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Pituitary incidentalomas</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Pituitary incidentalomas</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Pituitary incidentalomas</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Peter J Snyder, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David S Cooper, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kathryn A Martin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Apr 10, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The frequent detection of unsuspected anatomic abnormalities in many glands ("incidentalomas"), including the pituitary, made possible by the sensitivity of magnetic resonance imaging (MRI), raises the question of how to evaluate patients who have such an abnormality. The causes, evaluation, and treatment of pituitary incidentaloma are discussed here. The causes, clinical presentation, and evaluation of sellar masses are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/6632.html" rel="external">"Causes, presentation, and evaluation of sellar masses"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>The term "pituitary incidentaloma" refers to a previously unsuspected lesion that is detected on an imaging study performed for reasons other than pituitary symptoms or disease. Among adults undergoing imaging studies (computed tomography [CT] or magnetic resonance imaging [MRI]) for reasons other than pituitary symptoms or disease, the frequency of incidentally discovered signal abnormalities (&lt;10 mm) varies among studies from 4 to 20 percent by CT [<a href="#rid1">1-3</a>] and 10 to 38 percent by MRI [<a href="#rid4">4,5</a>].</p><p>Not all incidentally discovered sellar masses are pituitary adenomas. In one study of 61 incidentally discovered sellar masses found among 1000 unselected autopsy specimens, there were 37 Rathke's cleft cysts, 18 pituitary adenomas, and 2 each of hyperplasia, infarction, and hemorrhage [<a href="#rid6">6</a>]. However, pituitary adenomas are a common finding, as illustrated by a review of 29 autopsy studies that included over 18,000 pituitary glands [<a href="#rid7">7</a>]. The frequency of pituitary adenomas was approximately 10 percent, and nearly all of the adenomas were microadenomas (&lt;10 mm). The frequencies were similar for males and females and across age groups in adults.</p><p class="headingAnchor" id="H4"><span class="h1">CHARACTERISTICS OF REFERRED PATIENTS</span></p><p class="headingAnchor" id="H739915600"><span class="h2">Size</span><span class="headingEndMark"> — </span>Patients who are referred for evaluation of incidentally discovered magnetic resonance imaging (MRI) signal abnormalities within the sella tend to have larger lesions and a higher incidence of neurologic abnormalities than would be expected from autopsy and MRI series of unselected patients [<a href="#rid8">8,9</a>]. In one series of 328 referred patients, 233 (71 percent) had lesions 10 mm or larger [<a href="#rid10">10</a>]. This presumably reflects the selection process of a referral population. </p><p class="headingAnchor" id="H1118336996"><span class="h2">Adenoma type</span><span class="headingEndMark"> — </span>In the series of 328 patients with incidentally discovered incidentalomas [<a href="#rid10">10</a>], the following diagnoses were identified:</p><p class="bulletIndent1"><span class="glyph">●</span>179 (55 percent) nonfunctioning pituitary adenomas</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>47 (14 percent) Rathke's cleft cysts</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>37 (11 percent) lactotroph adenomas</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>16 (5 percent) somatotroph adenomas</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>7 (2 percent) corticotroph adenomas</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Over one-half had one or more hormonal deficiencies </p><p></p><p>In a prospective study of 131 patients who had incidentally discovered adenomas, 30 had hypogonadism, 13 had hypothyroidism, and 9 had secondary adrenal insufficiency [<a href="#rid11">11</a>].</p><p>The overall frequency of different types of pituitary adenomas is not known, because many large series of incidentally discovered sellar masses intentionally exclude those patients who have lesions that are hypersecreting. In our experience, however, it is common for a sellar mass that is discovered incidentally to be associated, on further evaluation, with obvious clinical consequences, including visual impairment and hormonal hypersecretion. Some of these patients even have obvious clinical manifestations of the hypersecretion (eg, acromegaly) that had been overlooked until the mass was discovered. Severe hormonal hyposecretion, including marked hypothyroidism and hypoadrenalism, can also be seen. </p><p class="headingAnchor" id="H5"><span class="h1">NATURAL HISTORY</span><span class="headingEndMark"> — </span>Information on the growth of nonfunctioning pituitary incidentalomas is somewhat limited. However, those ≥10 mm have some risk of growth [<a href="#rid12">12-14</a>], while those &lt;10 mm have a very low risk [<a href="#rid12">12,15</a>]. </p><p>In a systematic review and meta-analysis of studies that included 865 patients with incidentally discovered, nonfunctioning sellar masses, those ≥10 mm were approximately four times more likely to experience growth during follow-up than those &lt;10 mm (incidence 12.5 versus 3.3 per 100 person-years, respectively) [<a href="#rid14">14</a>]. </p><p>In a retrospective, longitudinal cohort of 177 patients with incidentally discovered nonfunctioning pituitary microadenomas (median size 4 mm) monitored with an average of four MRIs over a median follow-up period of five years, 63 percent of patients experienced no change or a decrease in size of their microadenomas [<a href="#rid15">15</a>]. However, 49 patients (28 percent) did experience an increase in size, but growth was slow with a maximal increase of 6 mm. These findings support the approach of less frequent imaging if the first follow-up MRI after initial diagnosis shows no change in size. (See <a class="local">'Lesions less than 10 mm'</a> below.) </p><p class="headingAnchor" id="H6"><span class="h1">EVALUATION AND MANAGEMENT</span><span class="headingEndMark"> — </span>Evaluation of a patient found incidentally to have a lesion within the pituitary depends upon the size of the lesion (<a class="graphic graphic_algorithm graphicRef80461" href="/z/d/graphic/80461.html" rel="external">algorithm 1</a>). Lesions 10 mm or larger are more likely to be associated with visual and hormonal abnormalities at the time they are discovered and are more likely to enlarge during observation than smaller lesions. (See  <a class="medical medical_review" href="/z/d/html/6627.html" rel="external">"Clinical manifestations and diagnosis of gonadotroph and other clinically nonfunctioning pituitary adenomas"</a>.)</p><p class="headingAnchor" id="H7"><span class="h2">Lesions 10 mm or larger</span><span class="headingEndMark"> — </span>These lesions should be evaluated as a symptomatic sellar mass of similar size. Vision should be evaluated clinically and by formal testing of acuity and fields. We suggest that these patients undergo clinical and biochemical evaluation for both hormone hypersecretion and hypopituitarism. For hypersecretion, this includes serum prolactin, insulin-like growth factor-1 (IGF-1) [<a href="#rid16">16</a>], luteinizing hormone (LH), follicle-stimulating hormone (FSH), and alpha subunit, corticotropin (ACTH), and 24-hour urine cortisol [<a href="#rid17">17</a>]. The evaluation of hypopituitarism is reviewed separately.(See  <a class="medical medical_review" href="/z/d/html/6632.html" rel="external">"Causes, presentation, and evaluation of sellar masses", section on 'Hormonal evaluation'</a> and  <a class="medical medical_review" href="/z/d/html/6639.html" rel="external">"Diagnostic testing for hypopituitarism"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Patients with pituitary adenomas resulting in hormonal hypersecretion (eg, hyperprolactinemia, acromegaly, or Cushing disease) should be treated as other patients with these disorders. (See  <a class="medical medical_review" href="/z/d/html/6630.html" rel="external">"Management of hyperprolactinemia"</a> and  <a class="medical medical_review" href="/z/d/html/6625.html" rel="external">"Treatment of acromegaly"</a> and  <a class="medical medical_review" href="/z/d/html/118.html" rel="external">"Primary therapy of Cushing disease: Transsphenoidal surgery and pituitary irradiation"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with gonadotroph adenomas and other clinically nonfunctioning lesions causing visual impairment or other neurologic symptoms, transsphenoidal surgery is the treatment of choice for initial therapy. (See  <a class="medical medical_review" href="/z/d/html/6631.html" rel="external">"Treatment of gonadotroph and other clinically nonfunctioning adenomas", section on 'Initial therapy: Transsphenoidal surgery'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with adenomas less than 20 mm without clinically important hormonal hypersecretion and no visual or other neurologic abnormalities, we suggest careful observation [<a href="#rid18">18</a>].These patients should be monitored for size of the mass, visual changes, and hormonal hypersecretion in 6 and 12 months, then annually for several years, and perhaps less frequently thereafter. Hormonal hyposecretion should be treated by appropriate replacement. (See  <a class="medical medical_review" href="/z/d/html/6640.html" rel="external">"Treatment of hypopituitarism"</a> and  <a class="medical medical_review" href="/z/d/html/6631.html" rel="external">"Treatment of gonadotroph and other clinically nonfunctioning adenomas", section on 'Asymptomatic adenomas'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Most patients whose adenomas are greater than 20 mm will have visual impairment or other neurologic symptoms that make reduction in size desirable. If there are no neurologic symptoms and the patient is an older adult and/or a poor surgical risk, observation is a reasonable course.</p><p></p><p class="headingAnchor" id="H8"><span class="h2">Lesions less than 10 mm</span><span class="headingEndMark"> — </span>Patients with smaller lesions should be evaluated clinically for hormonal hypersecretion and biochemically for any hypersecretion suspected clinically. Only serum prolactin should be measured if there is no clinical suspicion of hormonal hypersecretion, an approach that, in one report, was much more cost effective than either measurement of multiple hormones or performance of follow-up magnetic resonance imaging (MRI) at 6 and 12 months [<a href="#rid19">19</a>]. No evaluation for hormonal hyposecretion or visual abnormalities is necessary. Our approach differs from the 2011 Endocrine Society Guidelines, which recommend that patients with an incidentaloma of any size undergo initial testing for hormonal hypersecretion and hypopituitarism [<a href="#rid20">20</a>].</p><p>Patients with lesions not associated with hormonal hypersecretion may be treated as follows [<a href="#rid19">19</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>For patients with lesions 2 to ≤4 mm in diameter, we do not perform further testing as additional tests do not appear to affect outcome [<a href="#rid7">7</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with lesions &gt;4 to 9 mm in diameter, we monitor with pituitary MRI yearly for two years; if the lesion is stable in this period, the frequency can be decreased to every few years and then even less often.</p><p></p><p class="headingAnchor" id="H1560747628"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/116762.html" rel="external">"Society guideline links: Pituitary tumors and hypopituitarism"</a>.)</p><p class="headingAnchor" id="H3177503"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition </strong>– A pituitary incidentaloma is a previously unsuspected sellar mass that is detected on an imaging study performed for reasons other than pituitary symptoms or disease.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology </strong>–<strong> </strong>Pituitary incidentalomas are common. In imaging studies, the frequency of incidentally discovered pituitary lesions is 4 to 20 percent by computed tomography (CT) scan and 10 to 38 percent by magnetic resonance imaging (MRI). In autopsy studies, the frequency of previously unsuspected pituitary adenomas is approximately 10 percent. (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical characteristics </strong>–<strong> </strong>Patients who are referred for evaluation of incidentally discovered MRI abnormalities within the sella tend to have larger lesions and a higher incidence of neurologic abnormalities than would be expected from autopsy and MRI series of unselected patients. This presumably reflects the selection process of a referral population. (See <a class="local">'Characteristics of referred patients'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Natural history </strong>–<strong><em> </em></strong>Incidentally discovered sellar masses &gt;10 mm in diameter are more likely to grow than those &lt;10 mm. (See <a class="local">'Natural history'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation and management</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Pituitary incidentalomas ≥10 mm:</strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span>We perform evaluation for hormonal hyper- and hyposecretion (hypopituitarism). (See  <a class="medical medical_review" href="/z/d/html/6632.html" rel="external">"Causes, presentation, and evaluation of sellar masses", section on 'Hormonal evaluation'</a> and  <a class="medical medical_review" href="/z/d/html/6639.html" rel="external">"Diagnostic testing for hypopituitarism"</a>.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients with gonadotroph adenomas and other clinically nonfunctioning lesions causing visual impairment or other neurologic symptoms, we perform transsphenoidal surgery for initial therapy. This issue is reviewed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/6631.html" rel="external">"Treatment of gonadotroph and other clinically nonfunctioning adenomas", section on 'Initial therapy: Transsphenoidal surgery'</a>.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients with pituitary lesions ≥10 mm and symptoms related to clinically important hormonal hypersecretion (hyperprolactinemia, Cushing syndrome, acromegaly), treatment is described separately. (See  <a class="medical medical_review" href="/z/d/html/6630.html" rel="external">"Management of hyperprolactinemia"</a> and  <a class="medical medical_review" href="/z/d/html/6625.html" rel="external">"Treatment of acromegaly"</a> and  <a class="medical medical_review" href="/z/d/html/118.html" rel="external">"Primary therapy of Cushing disease: Transsphenoidal surgery and pituitary irradiation"</a>.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients with pituitary lesions ≥10 mm without neurologic symptoms or hormonal hypersecretion, we monitor with hormonal testing (for both hyper- and hyposecretion), visual testing, and pituitary MRI at 6 and 12 months during the first year. (See <a class="local">'Lesions 10 mm or larger'</a> above and  <a class="medical medical_review" href="/z/d/html/6631.html" rel="external">"Treatment of gonadotroph and other clinically nonfunctioning adenomas", section on 'Asymptomatic adenomas'</a>.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients with pituitary lesions ≥20 mm and visual impairment or other neurologic symptoms, treatment to reduce the size of the adenoma is indicated. However, if there are no neurologic symptoms and the patient is an older adult and/or a poor surgical risk, we choose observation. (See <a class="local">'Lesions 10 mm or larger'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>For patients with pituitary incidentalomas &lt;10 mm:</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>We measure only serum prolactin if there is no clinical suspicion of hormonal hypersecretion.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with lesions 2 to 4 mm in diameter, we do not perform further imaging tests.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For those with lesions between 5 to 9 mm in diameter, we perform MRI yearly for two years; if the lesion is stable in this period, the frequency can be decreased to every few years and then less often. (See <a class="local">'Lesions less than 10 mm'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Peyster RG, Adler LP, Viscarello RR, et al. CT of the normal pituitary gland. Neuroradiology 1986; 28:161.</a></li><li><a class="nounderline abstract_t">Wolpert SM, Molitch ME, Goldman JA, Wood JB. Size, shape, and appearance of the normal female pituitary gland. AJR Am J Roentgenol 1984; 143:377.</a></li><li><a class="nounderline abstract_t">Chambers EF, Turski PA, LaMasters D, Newton TH. Regions of low density in the contrast-enhanced pituitary gland: normal and pathologic processes. Radiology 1982; 144:109.</a></li><li><a class="nounderline abstract_t">Hall WA, Luciano MG, Doppman JL, et al. Pituitary magnetic resonance imaging in normal human volunteers: occult adenomas in the general population. Ann Intern Med 1994; 120:817.</a></li><li><a class="nounderline abstract_t">Chong BW, Kucharczyk W, Singer W, George S. Pituitary gland MR: a comparative study of healthy volunteers and patients with microadenomas. AJNR Am J Neuroradiol 1994; 15:675.</a></li><li><a class="nounderline abstract_t">Teramoto A, Hirakawa K, Sanno N, Osamura Y. Incidental pituitary lesions in 1,000 unselected autopsy specimens. Radiology 1994; 193:161.</a></li><li><a class="nounderline abstract_t">Molitch ME. Nonfunctioning pituitary tumors and pituitary incidentalomas. Endocrinol Metab Clin North Am 2008; 37:151.</a></li><li><a class="nounderline abstract_t">Reincke M, Allolio B, Saeger W, et al. The 'incidentaloma' of the pituitary gland. Is neurosurgery required? JAMA 1990; 263:2772.</a></li><li><a class="nounderline abstract_t">Donovan LE, Corenblum B. The natural history of the pituitary incidentaloma. Arch Intern Med 1995; 155:181.</a></li><li><a class="nounderline abstract_t">Imran SA, Yip CE, Papneja N, et al. Analysis and natural history of pituitary incidentalomas. Eur J Endocrinol 2016; 175:1.</a></li><li><a class="nounderline abstract_t">Freda PU, Bruce JN, Khandji AG, et al. Presenting Features in 269 Patients With Clinically Nonfunctioning Pituitary Adenomas Enrolled in a Prospective Study. J Endocr Soc 2020; 4:bvaa021.</a></li><li><a class="nounderline abstract_t">Sanno N, Oyama K, Tahara S, et al. A survey of pituitary incidentaloma in Japan. Eur J Endocrinol 2003; 149:123.</a></li><li><a class="nounderline abstract_t">Karavitaki N, Collison K, Halliday J, et al. What is the natural history of nonoperated nonfunctioning pituitary adenomas? Clin Endocrinol (Oxf) 2007; 67:938.</a></li><li><a class="nounderline abstract_t">Fernández-Balsells MM, Murad MH, Barwise A, et al. Natural history of nonfunctioning pituitary adenomas and incidentalomas: a systematic review and metaanalysis. J Clin Endocrinol Metab 2011; 96:905.</a></li><li><a class="nounderline abstract_t">Hordejuk D, Cheung YM, Wang W, et al. Long-Term Changes in the Size of Pituitary Microadenomas. Ann Intern Med 2023; 176:298.</a></li><li><a class="nounderline abstract_t">Wade AN, Baccon J, Grady MS, et al. Clinically silent somatotroph adenomas are common. Eur J Endocrinol 2011; 165:39.</a></li><li><a class="nounderline abstract_t">Karavitaki N, Ansorge O, Wass JA. Silent corticotroph adenomas. Arq Bras Endocrinol Metabol 2007; 51:1314.</a></li><li><a class="nounderline abstract_t">Dekkers OM, Hammer S, de Keizer RJ, et al. The natural course of non-functioning pituitary macroadenomas. Eur J Endocrinol 2007; 156:217.</a></li><li><a class="nounderline abstract_t">King JT Jr, Justice AC, Aron DC. Management of incidental pituitary microadenomas: a cost-effectiveness analysis. J Clin Endocrinol Metab 1997; 82:3625.</a></li><li><a class="nounderline abstract_t">Freda PU, Beckers AM, Katznelson L, et al. Pituitary incidentaloma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2011; 96:894.</a></li></ol></div><div id="topicVersionRevision">Topic 6642 Version 16.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3703239" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : CT of the normal pituitary gland.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6611072" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Size, shape, and appearance of the normal female pituitary gland.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7089241" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Regions of low density in the contrast-enhanced pituitary gland: normal and pathologic processes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8154641" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Pituitary magnetic resonance imaging in normal human volunteers: occult adenomas in the general population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8010269" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Pituitary gland MR: a comparative study of healthy volunteers and patients with microadenomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8090885" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Incidental pituitary lesions in 1,000 unselected autopsy specimens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18226735" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Nonfunctioning pituitary tumors and pituitary incidentalomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2332920" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : The 'incidentaloma' of the pituitary gland. Is neurosurgery required?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7811127" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : The natural history of the pituitary incidentaloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27037179" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Analysis and natural history of pituitary incidentalomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32258955" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Presenting Features in 269 Patients With Clinically Nonfunctioning Pituitary Adenomas Enrolled in a Prospective Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12887289" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : A survey of pituitary incidentaloma in Japan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17692109" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : What is the natural history of nonoperated nonfunctioning pituitary adenomas?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21474687" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Natural history of nonfunctioning pituitary adenomas and incidentalomas: a systematic review and metaanalysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36848656" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Long-Term Changes in the Size of Pituitary Microadenomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21493729" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Clinically silent somatotroph adenomas are common.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18209869" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Silent corticotroph adenomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17287411" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : The natural course of non-functioning pituitary macroadenomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9360517" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Management of incidental pituitary microadenomas: a cost-effectiveness analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21474686" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Pituitary incidentaloma: an endocrine society clinical practice guideline.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
